Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 300 Shares

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 300 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $78.03, for a total value of $23,409.00. Following the transaction, the president now owns 1,442,668 shares in the company, valued at approximately $112,571,384.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Stephen Hoge also recently made the following trade(s):

• On Monday, August 12th, Stephen Hoge sold 254 shares of Moderna stock. The shares were sold at an average price of $84.10, for a total value of $21,361.40.
• On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00.
• On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00.

Moderna Stock Down 0.2 %

Shares of MRNA opened at $77.40 on Friday. The stock has a fifty day simple moving average of $104.62 and a two-hundred day simple moving average of $112.80. The company has a quick ratio of 3.91, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $29.66 billion, a PE ratio of -4.94 and a beta of 1.67. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s revenue was down 29.9% compared to the same quarter last year. During the same period last year, the business earned ($3.62) earnings per share. As a group, equities analysts forecast that Moderna, Inc. will post -7.46 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Barclays cut their target price on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a research note on Friday, August 2nd. HSBC upgraded Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research note on Wednesday. Canaccord Genuity Group raised their target price on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday, May 3rd. Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday. Finally, Oppenheimer increased their price objective on Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, June 12th. Ten equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average target price of $123.79.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Cedar Wealth Management LLC raised its position in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the period. Commerzbank Aktiengesellschaft FI lifted its position in Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after buying an additional 93 shares during the last quarter. CVA Family Office LLC lifted its position in Moderna by 21.6% in the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after buying an additional 96 shares during the last quarter. Claro Advisors LLC boosted its stake in Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after buying an additional 108 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in shares of Moderna by 32.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after acquiring an additional 116 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.